% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Eskilsson:181427,
      author       = {E. Eskilsson and G. V. Røsland and G. M. Solecki$^*$ and
                      Q. Wang and P. N. Harter and G. Graziani and R. G. W.
                      Verhaak and F. Winkler$^*$ and R. Bjerkvig and H. Miletic},
      title        = {{EGFR} heterogeneity and implications for therapeutic
                      intervention in glioblastoma.},
      journal      = {Neuro-Oncology},
      volume       = {20},
      number       = {6},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2022-01995},
      pages        = {743 - 752},
      year         = {2018},
      note         = {POT Topic: 317},
      abstract     = {Patients with glioblastoma (GBM) have a universally poor
                      prognosis and are in urgent need of effective treatment
                      strategies. Recent advances in sequencing techniques
                      unraveled the complete genomic landscape of GBMs and
                      revealed profound heterogeneity of individual tumors even at
                      the single cell level. Genomic profiling has detected
                      epidermal growth factor receptor (EGFR) gene alterations in
                      more than half of GBMs. Major genetic events include
                      amplification and mutation of EGFR. Yet, treatment
                      strategies targeting EGFR have thus far failed in clinical
                      trials. In this review, we discuss the clonal and functional
                      heterogeneity of EGFRs in GBM development and critically
                      reassess the potential of EGFRs as therapeutic targets.},
      subtyp        = {Review Article},
      keywords     = {ErbB Receptors: antagonists $\&$ inhibitors / ErbB
                      Receptors: genetics / Glioblastoma: drug therapy /
                      Glioblastoma: genetics / Glioblastoma: pathology / Humans /
                      Molecular Targeted Therapy / Mutation / Prognosis / Protein
                      Kinase Inhibitors: therapeutic use / Protein Kinase
                      Inhibitors (NLM Chemicals) / EGFR protein, human (NLM
                      Chemicals) / ErbB Receptors (NLM Chemicals)},
      cin          = {G370},
      ddc          = {610},
      cid          = {I:(DE-He78)G370-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29040782},
      pmc          = {pmc:PMC5961011},
      doi          = {10.1093/neuonc/nox191},
      url          = {https://inrepo02.dkfz.de/record/181427},
}